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Small cell lung cancer (SCLC) histology in never smokershas been described rarely in the United States.1 Not
surprisingly, the risk factors for lung cancer in never smokers
usually pertain to non-small cell histology, with very little
data reported on the oncogenesis of SCLC in never smokers.
We present two cases of SCLC with a history of never
smoking.
CASE 1
A 47-year-old nonsmoker was diagnosed with SCLC
metastatic to mediastinum and right supraclavicular lymph
nodes. Smoking history was insignificant with only 40 cigars
consumed during his lifetime; however, secondhand smoke
(SHS) exposure occurred over a 2-year period during em-
ployment as a bartender. Positron emission tomography/
computed tomography (CT) scan showed a right upper lobe
primary tumor nodule, and right hilar, subcarinal, and right
supraclavicular adenopathy. Excisional biopsy of the right
supraclavicular mass revealed a poorly differentiated neu-
roendocrine tumor consistent with SCLC histology. Immu-
nohistochemical stains were positive for chromogranin, syn-
aptophysin, thyroid transcription factor-1 (TTF-1), and cell
adhesion molecule 5.2 (CAM 5.2) and were negative for
CK7, CK20, cytokeratins, and CD99. Chest radiation concur-
rent with cisplatin and etoposide was initiated, followed by
prophylactic cranial irradiation.
Fifteen months later, restaging CT scan revealed an
enlarged left supraclavicular node. After excisional lymph
node biopsy, immunohistochemical analysis confirmed
SCLC with positive staining for cytokeratin AE1 and AE3
and diffusely positive staining for synaptophysin and TTF-1.
No mutation in the epidermal growth factor receptor (EGFR)
was detected. He was started on two cycles of cisplatin and
etoposide and concurrent radiation to the left supraclavicular
area followed by two cycles of oral adjuvant topotecan,
which resulted in a complete response currently lasting 6
months from the time of recurrence.
CASE 2
An 80-year-old woman with no history of tobacco use
was diagnosed with limited stage SCLC. Treatment history
was significant for stage 2 breast cancer (T2, N0, estrogen
receptor (ER) and progesterone receptor (PR) positive) 24
years before diagnosis and primary biliary cirrhosis 11 years
before diagnosis. Breast cancer was treated with modified
radical mastectomy and 5 years of adjuvant tamoxifen. A
history of SHS exposure was reported over a 25-year period
of employment as a secretary. A CT scan showed a 4.6 
5.1  4.6 cm mass in the aortopulmonary window encasing
the left pulmonary artery, a 1.9-cm subcarinal lymph node,
and a mass in the left upper lobe of the lung measuring 2.5
2.1 cm with suspicious regional lymphangitic spread. Bron-
choscopic evaluation with biopsy of an endobronchial lesion
revealed poorly differentiated neuroendocrine cancer consis-
tent with small cell carcinoma. Immunohistochemical stains
were positive for CK7, MOC31, neuron specific enolase (NSE),
synaptophysin, and CD56 and were negative for CK20, TTF-1,
chromogranin CD57, and p53. Ki-67 marked greater than 90%
of nuclei. These morphologic and immunohistochemical profiles
were consistent with small cell carcinoma.
The patient successfully completed the radiation and
four cycles of concurrent carboplatin and etoposide, resulting
in a partial response with a residual tumor measuring 2.4 
2.3 cm. The patient is currently on surveillance, 4 months
after last therapy.
DISCUSSION
SHS exposure has been implicated in the pathogenesis
of both small cell and non-small cell variants of lung cancer.2
Although the causal link between SHS exposure and lung
cancer development is well established, it is not possible to
accurately estimate the risk for developing lung cancer con-
sequent to SHS exposure.
Several studies have implicated a variety of oncogenes
and tumor suppressor genes in the oncogenesis of SCLC,
including myc, EGFR, c-raf, c-fms, retinoblastoma, and p53.
N-myc mutation has been strongly associated with malignan-
cies with neuroendocrine properties, including SCLC.3 This
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finding is consistent with both of our cases, which showed
neuroendocrine features. EGFR mutation, though more com-
mon in non-small cell lung cancer, also occurs in SCLC. This
mutation was not detected in case 1 and not tested in case 2.
In another case report, however, EGFR-positive SCLC was
documented in a 72-year-old female nonsmoker.4 Interest-
ingly, gefitinib was capable of inhibiting EGFR signaling in
SCLC cell lines that express the receptor even at low levels.
This suggests that EGFR tyrosine kinase inhibitors could be
a novel treatment option for a subset of SCLC tumors that
express functional or mutated EGFR. In another report, two
cases of SCLCs in never smokers tested positive for EGFR
mutations.5 The occurrence of EGFR mutations in SCLC
patients who have never smoked should be evaluated and
warrants further study.
In addition, there has been cases reported of the occur-
rence of SCLC in patients with scleroderma who were never
smokers, leading to a positive association between SCLC and
interstitial pneumonitis because of scleroderma.6
In conclusion, sporadic cases of SCLC in never smok-
ers should be reported with analysis of potential risk factors
and tissue for elucidation of the oncogenesis of this unique
pathology.
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